Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease non-alcoholic fatty liver disease
Comorbidity C0011849|diabetes mellitus
Sentences 37
PubMedID- 20625647 Objective: to evaluate the frequency of non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (dm2) and to describe its risk factors.
PubMedID- 21554270 Role of type 2 diabetes mellitus in nonalcoholic fatty liver disease.
PubMedID- 26573192 Objective: to investigate the effect of body mass index (bmi) on new-onset non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm).
PubMedID- 26381272 Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.
PubMedID- 25303488 High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels.
PubMedID- 23507799 Therefore, nafld is strongly associated with type 2 diabetes mellitus and abdominal obesity.
PubMedID- 24505484 Conclusions: our results provide the first demonstration of a positive and independent association between nafld and avs in patients with type 2 diabetes mellitus.
PubMedID- 23663765 Conclusion: serum hscrp levels may be predictive of development of nafld in individuals with type 2 diabetes mellitus.
PubMedID- 24667697 The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
PubMedID- 25877002 The aggravation of mitochondrial dysfunction in nonalcoholic fatty liver disease accompanied with type 2 diabetes mellitus.
PubMedID- 24071688 Objective: to observe the effect of metformin on the expression of sirt1 and ucp2 in rat liver of type 2 diabetes mellitus (t2dm) with nonalcoholic fatty liver disease (nafld), and discuss the pathogenesis of t2dm with nafld, and the treatment with and possible mechanism of metformin.
PubMedID- 26573193 [relationship of socioeconomic status and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus].
PubMedID- 26147768 Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus.
PubMedID- 23341703 Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia.
PubMedID- 26339423 Prognostic value of high sensitivity c-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
PubMedID- 24919218 [advancement of researches on association of non-alcoholic fatty liver disease with type 2 diabetes mellitus].
PubMedID- 23843938 Nonalcoholic fatty liver disease (nafld) is closely associated with type 2 diabetes mellitus.
PubMedID- 25885947 High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels.
PubMedID- 23954219 Objective: to investigate the relationship between the resistin intronic +299g/a polymorphism and nonalcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm).
PubMedID- 26297218 Conclusions: higher vpt associates with markers of liver fibrosis due to nafld in diabetes mellitus.
PubMedID- 20627036 Methods: this trial involved 51 patients of type 2 diabetes mellitus with nafld (g4 group), 50 patients of type 2 diabetes alone (g3 group), 45 patients of nafld alone (g2 group) and 42 healthy control subjects (g1 group).
PubMedID- 22087177 nafld is frequently associated with obesity, diabetes mellitus and the metabolic syndrome.
PubMedID- 23489256 Aim: the aim of this case-control study was to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (t2dm) with non-alcoholic fatty liver disease (nafld).
PubMedID- 22927782 The aim of this study is to elucidate the effectiveness of liraglutide in nafld patients with type 2 diabetes mellitus (t2dm) compared to sitagliptin and pioglitazone.
PubMedID- 23969900 Increased body mass index and diabetes mellitus are associated with developing nafld and nash, which is a severe form of nafld.
PubMedID- 26198953 Objective: to investigate the association of serum pigment epithelium-derived factor (pedf) level and polymorphisms in pedf gene promoter region -358g-->a with non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm) of han nationality in fujian province.
PubMedID- 26201786 nafld was strongly associated with diabetes mellitus, glucose intolerance, body mass index >/=23, low high-density lipoprotein cholesterol, hypertriglyceridemia, and hypertension.
PubMedID- 22024083 Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus.
PubMedID- 23760677 Aims/hypothesis: we have previously reported a high prevalence of non-alcoholic fatty liver disease (nafld) among women with previous gestational diabetes mellitus (pgdm).
PubMedID- 24062606 There is a very high prevalence of nafld in individuals with type 2 diabetes mellitus.
PubMedID- 24961024 Gi: 52 patients diagnosed as nafld with diabetes mellitus type 2 or obesity or hyperlipedemia.
PubMedID- 24901133 Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus.
PubMedID- 25966055 Role of apn and tnf-alpha in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease.
PubMedID- 25243967 [analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
PubMedID- 20604719 Background and aims: non-alcoholic fatty liver disease (nafld) is strongly associated with obesity and diabetes mellitus.
PubMedID- 21886908 Type 2 diabetes mellitus-induced hyperglycemia in patients with nafld and normal lfts: relationship to lipid profile, oxidative stress and pro-inflammatory cytokines.
PubMedID- 24961607 The prevalence of diabetes mellitus was higher in patients with recurrent nafld (100% versus 37.5%, p < 0.01).

Page: 1